SIBP-R002 not checked
Shanghai Institute Of Biological Products
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Injection; strength: 12mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the…”In the company’s words, NCT06298071 on ClinicalTrials.gov
- Tested for
- Gout
- Main trialPhase 1
- “To evaluate the safety and tolerability of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs, to determine the recommended dose for phase II clinical trials, and to provide basis for formulation of administration regimen for phase II clinical trials.”In the company’s words, NCT06298071 on ClinicalTrials.gov
- Other names
- Peguricase for injection
Other drugs for Gout
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- EtoricoxibLaboratorios Silanes S.A. de C.V. · Phase 3
- DotinuradCrystalys Therapeutics · Phase 3
- AR882Arthrosi Therapeutics · Phase 2
- SSGJ-6133SBio · Phase 2
- PRX-115Protalix · Phase 2
Coming up1
- 30 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Dec 2026 | A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. | |
| Phase 1Completed | 9 Jan 2023 | A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026